Clinical use of non-a botulinum toxins: Botulinum toxin type B

Neurotoxicity Research

Volumn 9, Issue 2-3, 2006, Pages 121-125

  Dressler, Dirk ^a   Eleopra, Roberto ^b  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b UNIVERSITY HOSPITAL OF FERRARA   (Italy)

Author keywords

Antibodies; Anticholinergic adverse effects; Antigenicity; Botulinum toxin type A; Botulinum toxin type B; Systemic spread; Therapy

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN B;

ANIMAL; HUMAN; IMMUNOLOGY; NEUROMUSCULAR DISEASE; REVIEW;

ANIMALS; BOTULINUM TOXINS; HUMANS; NEUROMUSCULAR DISEASES;

EID: 33747164249     PISSN: 10298428     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03033929     Document Type: Article

References (28)

1. Baumann LS and ML Halem (2003) Systemic adverse effects after botulinum toxin type B (Myobloc) injections for the treatment of palmar hyperhidrosis. Arch. Dermatol. 139, 226-227.
2. Baumann L, A Slezinger, M Halem, J Vujevich, K Mallin, C Charles, LK Martin, L Black and J Bryde (2005) Double-blind, randomized, placebo-controlled pilot study of the safety and efficacy of Myobloc (botulinum toxin type B) for the treatment of palmar hyperhidrosis. Dermatol. Surg. 31, 263-270.
3. Benecke R, WH Jost, P Kanovsky, E Ruzicka, G Comes and S Grafe (2005) A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 64(11), 1949-1951.
4. Brashear A, AL McAfee, ER Kuhn and WT Ambrosius (2003) Treatment with botulinum toxin type B for upper-limb spasticity. Arch. Phys. Med. Rehabil. 84, 103-107.
5. Brashear A, MF Lew, DD Dykstra, CL Comella, SA Factor, RL Rodnitzky, R Trosch, C Singer, MF Brin, JJ Murray, JD Wallace, A Willmer-Hulme and M Koller (1999) Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 53, 1439-1446.
6. Brashear A, AL McAfee, ER Kuhn and WT Ambrosius (2003) Treatment with botulinum toxin type B for upper-limb spasticity. Arch. Phys. Med. Rehabil. 84, 103-107.
7. Brin MF, MF Lew, CH Adler, CL Comella, SA Factor, J Jankovic, C O'Brien, JJ Murray, JD Wallac, A Willmer-Hulme and M Koller (1999) Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 53, 1431-1438.
8. Comella CL, J Jankovic, KM Shannon, J Tsui, S Swenson, M Leurgans, W Fan, Dystonia Study Group (2005) Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 65, 1423-1429.
9. Consky ES, A Basinski, L Belle, R Ranawaya and AE Lang (1990) The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS), assessment of validity and inter-rater reliability. Neurology 40 (suppl. 1), 445
10. Dressler D (2003) Botulinum toxin B bei Kindern mit spastischen Bewegungsstörungen und funktioneller Hypersalivation. Akt. Neurol. 30, 470.
11. Dressler D (2004) Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Mov. Disord. Suppl. 8, S92-S100
12. Dressler D and R Benecke (2002) [Initial experiences with clinical use of botulinum toxin type B]. Nervenarzt 73, 194-198.
13. Dressler D and R Benecke (2003) Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur. Neurol. 49, 34-38.
14. Dressler D and H Bigalke (2005) Botulinum toxin type B de novo therapy of cervical dystonia, frequency of antibody-induced therapy failure. J. Neurol. 252, 904-907
15. Dressler D and M Hallett (2006) Immunological aspects of Botox®, Dysport®, and NeuroBloc®/MyoBloc™. Eur. J. Neurol. 13 Suppl. 1, 11-15.
16. Dressler D, F Adib Saberi and R Benecke (2002) Botulinum toxin type B for treatment of axillar hyperhidrosis. J. Neurol. 249, 1729-1732.
17. Dressler D, R Benecke and H Bigalke (2003) Botulinum toxin type B (NeuroBloc®) in patients with botulinum toxin type A antibody-induced therapy failure. J. Neurol. 250, 967-969
18. Dykstra D, A Enriquez and M Valley (2003) Treatment of overactive bladder with botulinum toxin type B, a pilot study. Int. Urogynecol. J. Pelvic Floor Dysfunct. 14, 424-426.
19. Fadeyi MO and QM Adams (2002) Use of botulinum toxin type B for migraine and tension headaches. Am. J. Health Syst. Pharm. 59, 1860-1862.
20. Health & Human Services, Public Health Service, Food and Drug Administration, Center for Biologics Evaluation and Research, Division of Clinical Trial Design and Analysis. MyoBloc, Summary Basis of Approval Cervical Dystonia. Supplemental Clinical Review. 2000. Available from US Government through Freedom of Information (http://www.fda.gov/cder/biologics/products/botelan120800.htm)
21. Jost WH (2001) Botulinum toxin type B in the treatment of anal fissures, first preliminary results. Dis. Colon Rectum 44, 1721-1722.
22. Kim EJ, AL Ramirez, JB Reeck and CS Maas (2003) The role of botulinum toxin type B (Myobloc) in the treatment of hyperkinetic facial lines. Plast. Reconstr. Surg. 112 (Suppl.), 88S-93S.
23. Lang AM (2004) Botulinum toxin type B in piriformis syndrome. Am. J. Phys. Med. Rehabil. 83, 198-202.
24. Oechsner M (2002) [Treatment of hip adductor spasticity with botulinum toxin type B]. Nervenarzt. 73, 1179-1182.
25. Racette BA, L Good, S Sagitto and JS Perlmutter (2003) Botulinum toxin B reduces sialorrhea in parkinsonism. Mov. Disord. 18, 1059-1061.
26. Sataloff RT, YD Heman-Ackah, LL Simpson, JB Park, A Zwislewski, C Sokolow and S Mandel (2002) Botulinum toxin type B for treatment of spasmodic dysphonia, a case report. J. Voice. 16, 322-324.
27. Schwerin A, S Berweck, UM Fietzek and F Heinen (2004) Botulinum toxin B treatment in children with spastic movement disorders, a pilot study. Pediatr. Neurol. 31, 109-113.
28. Tousi B, JS Perumal, K Ahuja, A Ahmed and T Subramanian (2004) Effects of botulinum toxin-B (BTX-B) injections for hemifacial spasm. Parkinsonism Relat. Disord. 10, 455-456.